The purpose of this trial is to assess the effect of switching CML patients, who have been
treated with imatinib ≥ 2 years and who have stable detectable molecular residual disease
between 0.01-1.0% (IS), to the combination of Nilotinib and PegIFN, in terms of the
proportion of patients who achieve confirmed MR4.0.
Phase:
Phase 2
Details
Lead Sponsor:
VU University Medical Center
Collaborators:
Merck Sharp & Dohme Corp. Novartis Uppsala University Hospital